Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Expands By 89.2%

Strata Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 679,358 shares, a growth of 89.2% from the January 29th total of 358,994 shares. Approximately 19.5% of the shares of the company are sold short. Based on an average trading volume of 895,841 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 895,841 shares, the days-to-cover ratio is presently 0.8 days. Approximately 19.5% of the shares of the company are sold short.

Strata Skin Sciences Trading Down 3.5%

Shares of SSKN stock opened at $0.25 on Friday. The stock has a market cap of $1.47 million, a P/E ratio of -0.09 and a beta of 0.33. The company has a quick ratio of 0.75, a current ratio of 0.95 and a debt-to-equity ratio of 10.22. Strata Skin Sciences has a fifty-two week low of $0.12 and a fifty-two week high of $3.86. The business has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.47.

Wall Street Analyst Weigh In

SSKN has been the subject of several research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Strata Skin Sciences from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Strata Skin Sciences

An institutional investor recently raised its position in Strata Skin Sciences stock. Azzad Asset Management Inc. ADV increased its stake in shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) by 81.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,800 shares of the medical device company’s stock after purchasing an additional 9,800 shares during the period. Azzad Asset Management Inc. ADV owned 0.41% of Strata Skin Sciences worth $45,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 32.43% of the company’s stock.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.